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354Objective: The objective of this study was to review the long-term results of symptomatic patients with Ebstein
anomaly in the neonatal period.
Methods: The medical records of 40 neonates with a diagnosis of Ebstein anomaly who were admitted to our
institution between January 1988 and June 2008 were retrospectively reviewed. Primary outcomes studied in-
cluded patient survival and need for reintervention.
Results: No early intervention was required in 16 of the 40 patients with a hospital survival of 94% (15/16) and
no late mortality. The remaining 24 patients underwent surgical intervention in the neonatal period. A shunt alone
was performed in 9 patients with an actuarial survival of 88.9% at 1 year and 76.2% at 5 and 10 years. For the
patients undergoing intervention on the tricuspid valve, survival estimates for the 11 patients with a right ventric-
ular exclusion procedure were 63.6% at 1, 5, and 10 years and 47.7% at 15 years compared with 25.0% at 1, 5,
and 10 years for the 4 patients with tricuspid valve repair. All long-term survivors were in New York Heart
Association class I or II, and only 1 patient required antiarrhythmic medication.
Conclusion: Symptomatic neonates with Ebstein anomaly requiring no intervention or shunting alone have good
long-term survival. For patients needing intervention on the tricuspid valve, overall survival is lower. For these
patients, right ventricular exclusion may be superior to tricuspid valve repair. (J Thorac Cardiovasc Surg
2010;139:354-8)Ebstein anomaly is a congenital malformation involving the
tricuspid valve and right ventricle (RV). The classic features
are apical displacement of the septal leaflet of the tricuspid
valve with a thin atrialized portion of RV in addition to
a malformed anterior leaflet, which may have anomalous
attachments in the RV outflow tract. This anomaly has a var-
iable clinical course. The age at presentation for patients
with Ebstein anomaly is bimodal, with patients presenting
as neonates or as older children and adults. For patients
with a severe form of Ebstein anomaly, there is a high
rate of fetal demise.1 Symptomatic neonates often are criti-
cally ill with a combination of congestive heart failure and
cyanosis resulting from decreased pulmonary blood flow,
tricuspid valve regurgitation, depressed RV function, and
low cardiac output.2 The management of the symptomatic
neonate remains challenging,3,4 and the optimal surgical
intervention is controversial inasmuch as there are several
operative options, including tricuspid valve repair or re-
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In an effort to understand the prognosis and optimal man-
agement of symptomatic neonates with Ebstein anomaly, we
retrospectively reviewed this group of patients at our institu-
tion. Major outcomes studied included patient survival and
need for reintervention.PATIENTS AND METHODS
Study Design
Between January 1988 and June 2008, all patients less than 30 days of
age admitted to the C.S. Mott Children’s Hospital, University of Michigan
Health Center, with Ebstein anomaly were included in this retrospective
study. Patients who had other complex cardiac anomalies not classically as-
sociated with Ebstein anomaly were excluded.
Approval from the Institutional ReviewBoard of the University ofMich-
igan was obtained. Medical records were reviewed with regard to the initial
clinical features, surgical intervention, and postoperative data. Echocardio-
grams conducted at admission were reviewed and the degree of tricuspid
valve regurgitation and Great Ormond Street (GOS) score were assessed.
The tricuspid valve regurgitation was qualitatively graded by color Doppler
using a scale of 0 (none) to 4 (severe), and the GOS score was determined
as a product of the combined area of the right atrium and the atrialized RV
divided by the area of the trabeculated RV and left-sided chambers, as
described by Celermajer and associates.3 Current follow-up data were
available for 36 (90%) of the 40 patients.
Management Protocol and Surgical Technique
The symptomatic neonate with Ebstein anomaly generally has cyanosis.
When pulmonary blood flow is ductus-dependent, a prostaglandin infusion
is administered to maintain pulmonary circulation. Complete anatomic eval-
uation with echocardiography is performed to assess the anatomy, particu-
larly the presence of structural or functional RV outflow tract obstruction.ery c February 2010
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GOS ¼ Great Ormond Street
RV ¼ right ventricle (ventricular)
SP ¼ systemic–pulmonary arteryFIGURE 1. Management protocol for neonates with Ebstein anomaly.
n represents number of patients for each group. CHF, Congestive heart fail-
ure; OR, operating room; PGE1, prostaglandin; RVOTO, right ventricular
outflow tract; SP, systemic–pulmonary artery; TV, tricuspid valve; RV, right
ventricle.
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of weaning from the prostaglandin infusion as the pulmonary vascular resis-
tance falls. A trial of nitric oxide to decrease pulmonary vascular resistance
may be helpful. If the wean is successful without congestive heart failure
and systemic saturations are maintained at greater than approximately
75%, no intervention is pursued in the neonatal period. If the wean is unsuc-
cessful owing to excessive cyanosis alone, an SP shunt is performed. If the
wean is unsuccessful owing to a combination of cyanosis and congestive
heart failure, an SP shunt alone will only mimic the condition seen with
prostaglandin support, and the tricuspid valve itself needs to be addressed.
In this situation, either RV exclusion or tricuspid valve repair is performed.
The decision to repair the valve depends on the anatomy and the likeli-
hood of successful repair. When repairing the tricuspid valve, we currently
prefer the Carpentier ‘‘cone’’ technique, which consists of detaching the an-
terior leaflet and reattaching it to the tricuspid valve annulus.6 The atrialized
portion of the RV is not plicated. In the RV exclusion procedure, the patch is
fenestrated if there is associated significant RV outflow tract obstruction or
atresia, and the coronary sinus is placed on either the RV side or right atrial
side at the surgeon’s preference, depending on the individual anatomy. The
atrialized RV is not routinely plicated. In either situation, the atrial defect is
kept open (Figure 1).
Statistical Analysis
Data are expressed as mean  standard deviation for continuous vari-
ables and as median and range for categorical variables. Among subgroups
of patients, the degree of tricuspid valve regurgitation and the GOS scores
were compared by the Student t test. The Kaplan–Meier estimate of opera-
tive survival was computed for all operative patients and for subgroups of
patients with each surgical procedure, and the survival estimates were com-
pared with the log–rank test. Stat Mate III software (ATMS Co, Tokyo,
Japan) was used for statistical analysis.
RESULTS
Patient Characteristics
All 40 patients who received a diagnosis of Ebstein anom-
aly before 30 days of age and were admitted to the C.S. Mott
Children’s Hospital during the study period were included.
Eighteen patients were male and 22 patients were female.
The median weight at the admission was 3.2 kg (range,
1.95–4.3 kg). Thirty-three of the 40 patients required a pros-
taglandin infusion to maintain their arterial oxygen satura-
tion. Patient characteristics are summarized in Table 1.
Preoperative Echocardiogram
The transthoracic echocardiograms from the time of ad-
mission were reviewed. The mean degree of tricuspid valve
regurgitation was 2.9  1.1 and the mean GOS score was
0.77  0.28. Regarding the RV outflow tract, 7 patients
had anatomic pulmonary atresia, 6 patients had functional
pulmonary atresia (no antegrade flow through the pulmo-
nary valve), and 7 patients had severe pulmonary stenosis
(minimal antegrade flow through the pulmonary valve).The Journal of Thoracic and CaOperative Interventions
After medical stabilization, 16 patients required no inter-
vention and 24 patients underwent surgical intervention dur-
ing the neonatal period according to the criteria previously
described. Among the 24 patients requiring surgical inter-
vention, the median age at the time of operation was 6
days (range, 1–17 days) and the median weight was 3.2 kg
(range, 2.5–4.1 kg). Eleven of the 24 patients underwent
an RV exclusion procedure (tricuspid valve closure with
SP shunt), 9 patients underwent an SP shunt with or without
patent ductus arteriosus ligation or atrial septectomy, and 4
patients underwent a tricuspid valve repair (Figure 1). Two
patients required tricuspid valve closure after an initial SP
shunt, 1 valve was closed 2 days after SP shunt, and the other
was closed at the time of stage II palliation (hemi-Fontan
procedure).
The degree of tricuspid valve regurgitation of the patients
who did not require intervention and those who underwent
surgical intervention was not significantly different (2.6 
1.0 vs 3.0  1.1, respectively). However, the GOS scorerdiovascular Surgery c Volume 139, Number 2 355
TABLE 1. Patient characteristics and associated lesions
Surgical intervention
All patients No intervention SP shunt RV exclusion TV repair
RVOT obstruction 20 6 4
VSD 2 2
Arrhythmia 3 1 (SVT) 2 (WPW, SVT)
Hydrops 1 1
Seizure activity 1 1
Rh incompatibility 1 1
Microsomal anomaly 1 1
Preoperative prostaglandin 33 9 9 11 4
Preoperative inotropes 16 5 2 7 2
Preoperative mechanical ventilation 17 5 4 4 3
Preoperative ECMO 3 1 2 1
RV, Right ventricular; SP, systemic–pulmonary artery; TV, tricuspid valve; RVOT, right ventricular outflow tract; VSD, ventricular septal defect; ECMO, extracorporeal membrane
oxygenation; SVT, supraventricular tachycardia; WPW, Wolff–Parkinson–White syndrome.
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did not require surgical intervention (0.89  0.29 vs 0.60 
0.17, respectively; P< .01). The degree of tricuspid valve
regurgitation among the patients who underwent SP shunt,
an RV exclusion procedure, and tricuspid valve repair was
not significantly different (2.7  1.3 vs 3.1  0.9 vs
3.6 0.5, respectively). However, the GOS scores of the pa-
tients who underwent tricuspid valve repair was significantly
greater than those of patients requiring only an SP shunt
(1.15  0.28 vs 0.73  0.27, respectively; P ¼ .03).
Among the 13 patients who underwent an RV exclusion
procedure in the neonatal period or at the time of the
hemi-Fontan procedure, 5 patients required fenestrated
patch closure of the tricuspid valve because of severe RV
outflow tract obstruction. The coronary sinus was situated
in the RV in 9 patients and in the right atrium in 4 patients.
Concomitant SP shunt was performed in all patients (modi-
fied Blalock–Taussig shunt in 7 patients and central shunt in
6), 3.5 or 4 mm in size, based on body weight.
Among the 4 patients who underwent tricuspid valve re-
pair, all required a pulmonary valvotomy or RV outflow tract
reconstruction, and 2 patients required an additional SP
shunt to maintain their arterial oxygen saturation.
Outcomes
Among the 16 patients who received no intervention, 15
patients survived the neonatal period and 2 patients were
lost to follow-up at a mean interval of 6.8 6.1 years. Three
patients required tricuspid valve repair later in life (at 4, 8,
and 13 years of age), and 1 patient required repair of coarc-
tation of the aorta at 1 year of age. Among the 24 neonates
undergoing an operation, there were 6 hospital deaths, 3
patients who underwent an RV exclusion procedure and 3
patients who underwent a tricuspid valve repair. There
were 4 late deaths among the 18 early survivors at a mean
follow-up of 7.2  5.1 years. All long-term survivors are
in New York Heart Association class I or II.356 The Journal of Thoracic and Cardiovascular SurgSubdividing the patients requiring intervention by proce-
dure revealed that among the 11 patients who underwent RV
exclusion, 8 (73%) survived to discharge. One patient sud-
denly died at home 3 months after the operation of an un-
known cause, 7 (63%) patients have had completion of
the Fontan procedure, and 1 patient died 11 years after the
Fontan procedure of severe systemic infection, including
sepsis, empyema, and endocarditis.
All 9 patients who underwent an SP shunt survived to dis-
charge. One patient required extracorporeal membrane
oxygenation support and tricuspid valve closure early post-
operatively. Two patients have had completion of a Fontan
procedure, 1 patient underwent tricuspid valve replacement
and RV–pulmonary artery conduit, 1 patient underwent
1-and-one-half ventricle repair, and 1 patient is awaiting
a Fontan procedure after tricuspid valve closure at the time
of a stage II procedure. There were 2 late deaths; 1 patient
died at the time of stage II palliation because of hypoxemia
and low cardiac output syndrome, and 1 patient died at the
time of Fontan procedure because of severe ventricular dys-
function. Two patients were lost to follow-up.
Among 4 patients who underwent tricuspid valve repair,
there were 3 hospital deaths; the fourth patient survived
and is doing well without reoperation for 12.5 years
(Figure 2).
The overall survival estimate for all patients undergoing
surgical intervention was 66.7% at 1 year, 62.2% at 5 and
10 years, and 51.9% at 15 years. The survival estimates
for patients who underwent an RV exclusion procedure
were 63.6% at 1, 5, and 10 years and 47.7% at 15 years.
For the patients who underwent an SP shunt, the actuarial
survival was 88.9% at 1 year and 76.2% at 5 and 10 years.
For patients who underwent a tricuspid valve repair, the ac-
tuarial survival was 25.0% at 1, 5, and 10 years (Figure 3).
There was a significant statistical difference in the survival
estimates between the patients with an SP shunt and those
with tricuspid valve repair (log–rank test, P ¼ .019).ery c February 2010
FIGURE 2. Postoperative clinical outcome for each procedure. n represents number of patients for each group. RV, Right ventricle; RV-PA, right ventricle–
pulmonary artery conduit; SP, systemic–pulmonary artery; TV, tricuspid valve; TVR, tricuspid valve replacement.
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Management of the symptomatic neonate with Ebstein
anomaly has been controversial and challenging. Some neo-
nates with this anomaly can be successfully managed with-
out intervention and may undergo tricuspid valve repair later
in life, but others can have severe cyanosis with or without
congestive heart failure requiring early surgical intervention.
Historically, the neonatal mortality for this anomaly has
been high. However, recent surgical interventions to im-
prove early survival have been successful.3,4,7
In the current study, 40% of the symptomatic neonates
with Ebstein anomaly required no immediate surgical inter-
vention. The overall hospital survival for this group was ex-
cellent at 94% (15/16) with no late deaths. To date, only 3 of
these patients have required tricuspid valve repair later in life
and all remain in good health. It would seem intuitively cor-
rect that the patients not requiring intervention would have
a milder form of the disease. Indeed, even though we were
unable to detect a difference in the degree of tricuspid regur-
gitation between groups requiring surgical intervention or
not, there was a significant difference in the GOS score. Al-
though the GOS score may be a surrogate for severity of dis-The Journal of Thoracic and Caease, we would not advocate for either GOS score or degree
of tricuspid regurgitation to be used as the sole determinant
for the need for surgical intervention. This decision is based
more appropriately on the patient’s ability to tolerate wean-
ing from a prostaglandin infusion.
Prostaglandin weaning will fail because of unacceptable
cyanosis in a subgroup of patients, and they will require in-
tervention in the neonatal period. When receiving prosta-
glandin, if the patient has an acceptable systemic oxygen
saturation without congestive heart failure, an SP shunt is
a reasonable option. The use of an SP shunt alone allows
for future options, including Fontan, one-and-one-half ven-
tricle repair, and biventricular repair. The results of SP shunt
alone were good, with an actuarial survival of 88.9% at 1
year and 76.2% at 5 and 10 years.
For patients with both cyanosis and congestive heart fail-
ure while receiving prostaglandin, the tricuspid valve will
need to be addressed. The options include tricuspid valve
repair or replacement and RV exclusion. Tricuspid valve
repair is challenging in the neonate because of the complex
anatomy and fragile neonatal valve tissue. More important,
this anomaly is not isolated to the tricuspid valve. Rather,rdiovascular Surgery c Volume 139, Number 2 357
FIGURE 3. Kaplan–Meier estimates of operative survival. Thick solid line,All operative patients; thin solid line, right ventricular (RV) exclusion procedure;
wide dotted line, systemic&pulmonary artery (SP) shunt; narrow dotted line, tricuspid valve repair.
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of diminished RV function and volume, in addition to RV
outflow tract obstruction. Although excellent midterm re-
sults of tricuspid valve repair for neonatal Ebstein anomaly
have been reported, these results are institution-dependent,
and few institutions have been able to duplicate these results
for tricuspid valve repair.8,9 Our outcomes for tricuspid
valve repair in the neonatal period have been disappointing,
with only 1 of 4 neonates surviving to discharge. The re-
maining 3 patients could not be weaned from cardiopulmo-
nary bypass after tricuspid valve repair owing to severe
cyanosis and hypotension. The intraoperative transesopha-
geal echocardiogram suggested that the RV could not gener-
ate adequate pulmonary blood flow even with a more
competent tricuspid valve and nonrestrictive RV outflow
tract. We have largely abandoned neonatal tricuspid valve
repair, except in cases of favorable tricuspid valve, RV,
and RV outflow tract anatomy.
The other option for these neonates is RV exclusion.
Since Starnes and his colleagues5 published their early expe-
rience with RV exclusion in 1991, this procedure has been
widely used for symptomatic neonates who have both cya-
nosis and congestive heart failure.10 This procedure can re-
duce right heart dilatation by excluding the RV from the
circulation; moreover, it can improve left ventricular dimen-
sion and function.11 The technique applied at our institution
includes selective patch fenestration depending on the de-
gree of RV outflow tract obstruction, placement of the coro-
nary sinus on either the atrial or ventricular side of the patch
depending on surgeon preference, and no plication of the at-
rialized portion of the RV. The early survival of patients with
RV exclusion in our population was 72.7%, which is similar
to other reported series.8,10
Ebstein anomaly represents a spectrum of disease with
a variable need for surgical intervention. Optimally, neo-
nates with symptomatic Ebstein anomaly can be weaned
successfully from prostaglandin and discharged without
the need for intervention. For those patients who cannot be358 The Journal of Thoracic and Cardiovascular Surgweaned from prostaglandin, an SP shunt alone can be used
if congestive heart failure is absent. For patients with both
cyanosis and congestive heart failure necessitating tricuspid
valve intervention in the newborn period, our data would
suggest that RV exclusion (tricuspid valve closure with an
SP shunt) results in the most favorable outcome. Although
tricuspid valve repair allows for biventricular anatomy and
remains an important part of the surgeon’s armamentarium
for older children, it is best reserved for those neonates
with the most favorable anatomy based on preoperative
and intraoperative assessment.References
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